Canaccord Genuity raised its price target on Hims & Hers to $40, citing stronger sales momentum in weight-loss drugs and peptide opportunities.
Hims & Hers Health stock rallied on Canaccord Genuity’s raised price target of $40, marking the Street-high call for the […]








